Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant CellsMatthew J. Martin(Abzena (United Kingdom)), Paul D. Smith(Abzena (United Kingdom))Cancer Research CommunicationsSeptember 12, 202210.1158/2767-9764.crc-22-0066Cited by 8SaveCiteExport RISWatch citationsRelated PapersThe MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models|British Journal of Cancer|2012|111